3 citations
,
March 2022 in “Journal of Infection” This study observed that SARS-CoV-2 shedding significantly decreased after remdesivir treatment, irrespective of RT-PCR cycle threshold values, suggesting early de-isolation might be possible in severe COVID-19 cases.
198 citations
,
April 2020 in “Journal of Endocrinological Investigation” This study found no SARS-CoV-2 RNA in the semen and urine of a COVID-19 patient, suggesting possible viral clearance or absence in these fluids.
4 citations
,
October 2020 in “Research Square (Research Square)” In this study, hydroxychloroquine, nitazoxanide, and ivermectin demonstrated similar efficacy for overall clinical outcomes in COVID-19 when administered early with azithromycin, vitamins, and supplements, with nitazoxanide showing the strongest antiviral activity and safety profile among the three.
22 citations
,
October 2021 in “Dermatologic Therapy” This study found that approximately one-quarter of post-COVID-19 patients experienced telogen effluvium, with a higher incidence among women, hospitalized patients, and those with hypertension or respiratory symptoms.
April 2021 in “Bioscientia Medicina Journal of Biomedicine and Translational Research” This report describes a severe COVID-19 case in a patient with SLE and nephritis, where hydroxychloroquine improved outcomes after regular use.
